BRIEF-Protagonist Announces Plans To Initiate A Global Phase 3 Study For Rusfertide In Polycythemia Vera
BRIEF-Protagonist Announces Plans To Initiate A Global Phase 3 Study For Rusfertide In Polycythemia Vera
* PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
* PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 22 (Reuters) - Protagonist Therapeutics Inc :
* PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
* PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月22日电-主角治疗公司：*Protagant宣布计划在与美国食品和药物管理局(FDA)和欧洲药品管理局(European Drug Agency)互动后，启动RUSFERTIDE治疗真性红细胞增多症的全球3期研究*主角-与FDA的第二阶段结束会议，以及EMA的书面意见，支持推进RUSFERTIDE在PV中的临床开发计划Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧